表紙:集団シーケンシングの世界市場 - 分析と予測:製品・手法・技術・用途・国・競合情勢への注目 (2020-2030年)
市場調査レポート
商品コード
963422

集団シーケンシングの世界市場 - 分析と予測:製品・手法・技術・用途・国・競合情勢への注目 (2020-2030年)

Global Population Sequencing Market: Focus on Product, Method, Technology, Application, Country, and Competitive Landscape - Analysis and Forecast, 2020-2030

出版日: | 発行: BIS Research Inc. | ページ情報: 英文 200 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.68円
集団シーケンシングの世界市場 - 分析と予測:製品・手法・技術・用途・国・競合情勢への注目 (2020-2030年)
出版日: 2020年09月30日
発行: BIS Research Inc.
ページ情報: 英文 200 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の集団シーケンシング市場規模は、2030年までに640億4760万米ドルへ達すると予測されています。

当レポートでは、世界の集団シーケンシング市場について取り上げ、市場ダイナミクス、競合環境、各セグメント・地域別の市場、競合状況、および主要企業などについて詳細に分析しています。

目次

エグゼクティブサマリー

第1章 製品の定義

  • 定義:製品別
    • プラットフォーム
    • キットとアッセイ
    • ソフトウェアツール
  • 包含と除外
  • 作業範囲
  • レポートで回答された重要な質問

第2章 調査手法

  • 一次データソース
  • 二次データソース
  • 市場推計モデル
  • 企業プロファイリングの基準

第3章 イントロダクション

  • 市場概要
  • 集団シーケンシングに対するCOVID-19の影響
  • 将来の可能性

第4章 世界の人口シーケンシング市場力学

  • 概要
  • 影響分析
  • 市場の促進要因
    • COVID-19からの感受性および耐性のゲノミクスを理解するための大規模シーケンシングの採用の高まり
    • 遺伝性疾患のスクリーニングと診断のための個別化医療の採用の増加
    • Direct-to-Consumer(DTC)遺伝子検査の世界の急増
  • 市場の抑制要因
    • 機密性の高いゲノムデータを維持、保存、共有するためのインフラストラクチャの不足
    • ハイスループットゲノムソフトウェアツールの開発のための十分な資金の不足
    • 臨床診療におけるデータの還元性と翻訳性の低さ
  • 市場機会
    • ブロックチェーンを活用した人工知能による精密医療の進歩
    • 集団シーケンシング向けサンプル調製における技術的進歩
    • 集団エンゲージメントとデータ管理の増加

第5章 競合情勢

  • 主な戦略と開発
    • 製品の承認
    • 製品の発売とアップグレード
    • 相乗効果
    • 資金調達と拡大
    • 買収
    • その他

第6章 業界考察

  • 概要
  • 米国の法的要件とフレームワーク
  • 欧州の法的要件とフレームワーク
  • アジア太平洋の法的要件とフレームワーク
    • 日本
  • 市場シェア分析:企業別
    • 成長シェア分析(機会マッピング)
    • 企業別

第7章 世界の集団シーケンシングイニシアチブ:国別

  • 米国
  • カナダ
    • 集団シーケンシングプログラム
  • 英国
    • ゲノム医学の方向を定める業界パートナーシップ
  • エストニア
  • ドイツ
  • フランス
  • アイルランド
  • オランダ
  • デンマーク
  • 日本
  • 中国
  • オーストラリア
  • サウジアラビア
  • カタール
  • トルコ
  • ドバイ

第8章 世界の集団シーケンシング市場:製品別

  • イントロダクション
  • キットとアッセイ
  • プラットフォーム
  • ソフトウェアツール

第9章 世界の集団シーケンシング市場:手法別

  • イントロダクション
  • 全ゲノムシーケンス
  • 全エクソームシーケンス
  • シングルリードシーケンス
  • その他のシーケンス方法

第10章 世界の集団シーケンシング市場:技術別

  • イントロダクション
  • ポリメラーゼ連鎖反応(PCR)
  • 次世代シーケンシング(NGS)
  • その他のテクノロジー

第11章 世界の集団シーケンシング市場:用途別

  • イントロダクション
  • 人間の健康
    • 臨床用途
    • 橋渡し研究/トランスレーショナルリサーチシーケンシング
  • 分子法医学
  • ゲノミクスにおけるブロックチェーン
    • データの共有と収益化
    • データストレージとセキュリティ
    • 自動健康保険

第12章 世界の集団シーケンシング市場:国別

  • 米国
  • カナダ
  • 英国
  • ドイツ
  • デンマーク
  • アイルランド
  • エストニア
  • フィンランド
  • オランダ
  • 中国
  • 日本
  • サウジアラビア
  • トルコ
  • カタール

第13章 企業プロファイル

  • Agilent Technologies, Inc.
  • Beijing Genomics Institute (BGI)
  • Color Genomics, Inc.
  • F. Hoffmann-La Roche Ltd
  • Genuity Science
  • Helix OpCo, LLC
  • Illumina, Inc.
  • Nebula Genomics, Inc.
  • Oxford Nanopore Technologies, Inc.
  • Pacific Biosciences of California, Inc.
  • QIAGEN N.V.
  • Thermo Fisher Scientific Inc.
図表

List of Tables

  • Table 4.1: Likert Scale
  • Table 4.2: Impact Analysis of Market Drivers
  • Table 4.3: Impact Analysis of Market Restraints
  • Table 4.4: Per Sample Clinical Cost of WGS and WES
  • Table 7.1: Population Sequencing Initiative in U.S.
  • Table 7.2: Funding Allocated to Different Agencies
  • Table 7.3: Population Sequencing Initiative in Canada
  • Table 7.4: National and International Initiatives in Canada
  • Table 7.5: Ongoing Population Sequencing Program
  • Table 7.6: Population Sequencing Initiatives in the U.K.
  • Table 7.7: Key Investments Driving Genomic Medicine in the U.K.
  • Table 7.8: Genomic Medicine Centers in the U.K.
  • Table 7.9: Population Genomic Initiatives in Estonia
  • Table 7.10: Population Genomic Initiatives in Germany
  • Table 7.11: Population Genomic Initiatives in France
  • Table 7.12: French Genomic Platform
  • Table 7.13: Population Genomic Initiatives in Ireland
  • Table 7.14: Population Genomic Initiatives in Netherlands
  • Table 7.15: Population Genomic Initiatives in Denmark
  • Table 7.16: Population Sequencing Initiative in Japan
  • Table 7.17: Population Sequencing Initiative in China
  • Table 7.18: Population Sequencing Initiative in Australia
  • Table 7.19: Population Sequencing Initiative in Saudi Arabia
  • Table 7.20: Genome Sequencing Centers
  • Table 7.21: Population Sequencing Initiative in Qatar
  • Table 7.22: Population Sequencing Initiative in Turkey
  • Table 7.23: Population Sequencing Initiative in Dubai
  • Table 8.1: Market Available Sequencing Kits and Assays
  • Table 8.2: Market Available Population Sequencing Platforms
  • Table 8.3: Market Available Population Sequencing Software Tools

List of Figures

  • Figure 1: Total Global Disease Burden (by Cause), 2010- 2017
  • Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Global Population Sequencing Market
  • Figure 3: Global Population Sequencing Market (by Product Type), $Million, 2020 vs. 2030
  • Figure 4: Global Population Sequencing Market (by Application), $Million, 2020 vs. 2030
  • Figure 5: Global Population Sequencing Market (by Method), $Million, 2020 vs. 2030
  • Figure 6: Global Population Sequencing Market (by Technology), $Million, 2020 vs. 2030
  • Figure 7: Global Population Sequencing Market Snapshot
  • Figure 1.1: Global Population Sequencing Market Segments Primary Research Methodology
  • Figure 2.1: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 2.2: Top-Down Approach (Segment-Wise Analysis)
  • Figure 3.1: Evolution of Population Sequencing
  • Figure 3.2: Active Population Sequencing Initiatives
  • Figure 4.1: U.S. Prevalence of Lyme Disease 2009-2018:
  • Figure 4.2: Global Prevalence Rate of Selected Rare Diseases Per 100,000 People
  • Figure 4.3: Number of People Tested by Consumer Genetics Companies (as of 2019)
  • Figure 5.1: Share of Key Developments and Strategies, 2017-2020
  • Figure 5.2: Product Approval Share (by Company), 2017-2020
  • Figure 5.3: Product Launch and Upgradation Share (by Company), 2017-2020
  • Figure 5.4: Synergistic Activities Share (by Company), 2017-2020
  • Figure 5.5: Funding and Expansion Share (by Company), 2017-2020
  • Figure 5.6: Acquisitions Share (by Company), 2017-2020
  • Figure 5.7: Other Key Development Share (by Company), 2017-2020
  • Figure 6.1: Regulatory Scenario in Europe (by Country)
  • Figure 6.2: Assessment of Commercialization Strategy in Japan
  • Figure 6.3: Market Share Analysis for the Global Population Sequencing Market 2019
  • Figure 6.4: Growth Share Matrix for Global Population Sequencing Market (by Company), 2019
  • Figure 7.1: Genome Centers in Canada
  • Figure 7.2: Member of the GENE Consortium
  • Figure 8.1: Global Population Sequencing Market (by Product), $Million, 2019-2030
  • Figure 8.2: Global Population Sequencing Market (Kits and Assays), $Million, 2019-2030
  • Figure 8.3: Global Population Sequencing Market (by Platforms), $Million, 2019-2030
  • Figure 8.4: Global Population Sequencing Market (by Software tools), $Million, 2019-2030
  • Figure 9.1: Global Population Sequencing Market (by Methods), $Million, 2019-2030
  • Figure 9.2: Global Population Sequencing Market (Whole Genome Sequencing), $Million, 2019-2030
  • Figure 9.3: Global Population Sequencing Market (Whole Exome Sequencing), $Million, 2019-2030
  • Figure 9.4: Global Population Sequencing Market (Single-Read Sequencing), $Million, 2019-2030
  • Figure 9.5: Global Population Sequencing Market (Other Sequencing Methods), $Million, 2019-2030
  • Figure 10.1: Global Population Sequencing Market (by Technology), $Million, 2019-2030
  • Figure 10.2: Global Population Sequencing Market (PCR), $Million, 2019-2030
  • Figure 10.3: Global Population Sequencing Market (NGS), $Million, 2019-2030
  • Figure 10.4: Global Population Sequencing Market (Other Technologies), $Million, 2019-2030
  • Figure 11.1: Global Population Sequencing Market (by Application), $Million, 2019-2030
  • Figure 11.2: Global Population Sequencing Market (Human Health), $Million, 2019-2030
  • Figure 11.3: Global Population Sequencing Market (by Human Heath Application), $Million, 2019-2030
  • Figure 11.4: Global Population Sequencing Market (by Clinical Application), $Million, 2019-2030
  • Figure 11.5: Global Population Sequencing Market (by Clinical Application), $Million, 2019-2030
  • Figure 11.6: Global Population Sequencing Market (Diagnostics Application) ($Million), 2019-2030
  • Figure 11.7: Global Population Sequencing Market (Diagnostics Application) ($Million), 2019-2030
  • Figure 11.8: Global Population Sequencing Market (Cancer Diagnostics), $Million, 2019-2030
  • Figure 11.9: Global Population Sequencing Market (Infectious Disease Diagnostics), $Million, 2019-2030
  • Figure 11.10: Global Population Sequencing Market (Rare Disease Diagnostics), $Million, 2019-2030
  • Figure 11.11: Global Population Sequencing Market (Other Diagnostics), $Million, 2019-2030
  • Figure 11.12: Global Population Sequencing Market (Diagnostics Application), $Million, 2019-2030
  • Figure 11.13: Global Population Sequencing Market (Translational Research), $Million, 2019-2030
  • Figure 11.14: Global Population Sequencing Market (Molecular Forensics), $Million, 2019-2030
  • Figure 11.15: Global Population Sequencing Market (Blockchain in Genomics), $Million, 2019-2030
  • Figure 11.16: Global Population Sequencing Market (Blockchain in Genomics), $Million, 2019-2030
  • Figure 11.17: Global Population Sequencing Market (Data Sharing and Monetization), $Million, 2019-2030
  • Figure 11.18: Global Population Sequencing Market (Data Storage and Security), $ Millions, 2019-2030
  • Figure 11.19: Global Population Sequencing Market (Automated Health Insurance), $Millions, 2019-2030
  • Figure 12.1: Global Population Sequencing Market (by Country), $Million, 2020 and 2030
  • Figure 12.2: U.S. Population Sequencing Market $Million, 2019-2030
  • Figure 12.3: Canada Population Sequencing Market $Million, 2019-2030
  • Figure 12.4: U.K. Population Sequencing Market $Million, 2019-2030
  • Figure 12.5: Germany Population Sequencing Market $Million, 2019-2030
  • Figure 12.6: Denmark Population Sequencing Market $Million, 2019-2030
  • Figure 12.7: Ireland Population Sequencing Market $Million, 2019-2030
  • Figure 12.8: Estonia Population Sequencing Market $Million, 2019-2030
  • Figure 12.9: Finland Population Sequencing Market $Million, 2019-2030
  • Figure 12.10: Netherlands Population Sequencing Market $Million, 2019-2030
  • Figure 12.11: China Population Sequencing Market $Million, 2019-2030
  • Figure 12.12: Japan Population Sequencing Market $Million, 2019-2030
  • Figure 12.13: Saudi Arabia Population Sequencing Market $Million, 2019-2030
  • Figure 12.14: Saudi Arabia Population Sequencing Market $Million, 2019-2030
  • Figure 12.15: Qatar Population Sequencing Market $Million, 2019-2030
  • Figure 13.1: Total Number of Companies Profiled
  • Figure 13.2: Agilent Technologies, Inc.: Product Portfolio
  • Figure 13.3: Agilent Technologies, Inc.: Overall Financials, 2017-2019
  • Figure 13.4: Agilent Technologies, Inc.: Revenue (by Segment), 2017-2019
  • Figure 13.5: Agilent Technologies, Inc.: Revenue (by Region), 2017-2019
  • Figure 13.6: Agilent Technologies, Inc.: R&D Expenditure, 2017-2019
  • Figure 13.7: Agilent Technologies, Inc.: SWOT Analysis
  • Figure 13.8: BGI:Product Portfolio
  • Figure 13.9: BGI: SWOT Analysis
  • Figure 13.10: Color Genomic, Inc.: Product Portfolio
  • Figure 13.11: Color Genomics, Inc.: SWOT Analysis
  • Figure 13.12: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
  • Figure 13.13: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2017-2019
  • Figure 13.14: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2017-2019
  • Figure 13.15: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
  • Figure 13.16: F. Hoffmann-La Roche Ltd: SWOT Analysis
  • Figure 13.17: Genuity Science.: Overall Product Portfolio
  • Figure 13.18: Genuity Science: SWOT Analysis
  • Figure 13.19: Helix Opco LLC: Product Portfolio
  • Figure 13.20: Helix Opco, LLC: SWOT Analysis
  • Figure 13.21: Illumina, Inc.: Overall Product Portfolio
  • Figure 13.22: Illumina, Inc.: Overall Financials, 2017-2019
  • Figure 13.23: Illumina, Inc.: Revenue (by Segment), 2017-2019
  • Figure 13.24: Illumina, Inc.: Revenue (by Region), 2017-2019
  • Figure 13.25: Illumina, Inc.: R&D Expenditure, 2017-2019
  • Figure 13.26: Illumina, Inc.: SWOT Analysis
  • Figure 13.27: Nebula Genomics, Inc.: Overall Product Portfolio
  • Figure 13.28: Nebula Genomics, Inc.: SWOT Analysis
  • Figure 13.29: Oxford Nanopore Technologies, Inc.: Product Offerings
  • Figure 13.30: Oxford Nanopore Technologies, Inc.: SWOT Analysis
  • Figure 13.31: Pacific Biosciences of California, Inc.: Overall Product Portfolio
  • Figure 13.32: Pacific Biosciences of California, Inc.: Overall Financials, 2017-2019
  • Figure 13.33: Pacific Biosciences of California, Inc.: Revenue (By Segment), 2017-2019
  • Figure 13.34: Pacific Biosciences of California, Inc.: Revenue (by Region), 2017-2019
  • Figure 13.35: Pacific Biosciences of California, Inc.: R&D Expenditure, 2017-2019
  • Figure 13.36: Pacific Biosciences of California, Inc.: SWOT Analysis
  • Figure 13.37: QIAGEN N.V.: Product Portfolio
  • Figure 13.38: QIAGEN N.V.: Overall Financials, 2017-2019
  • Figure 13.39: QIAGEN N.V.: Revenue (by Product Segment), 2017-2019
  • Figure 13.40: QIAGEN N.V.: Revenue (by Segment), 2017-2019
  • Figure 13.41: QIAGEN N.V.: Revenue (by Region), 2017-2019
  • Figure 13.42: QIAGEN N.V.: R&D Expenditure, 2017-2019
  • Figure 13.43: QIAGEN N.V.: SWOT Analysis
  • Figure 13.44: Thermo Fisher Scientific Inc.: Product Portfolio
  • Figure 13.45: Thermo Fisher Scientific Inc.: Overall Financials, 2017-2019
  • Figure 13.46: Thermo Fisher Scientific Inc.: Revenue (by Segment), 2017-2019
  • Figure 13.47: Thermo Fisher Scientific Inc.: Revenue (by Region), 2017-2019
  • Figure 13.48: Thermo Fisher Scientific Inc.: R&D Expenditure, 2017-2019
  • Figure 13.49: Thermo Fisher Scientific Inc.: SWOT Analysis
目次
Product Code: BHP0971SA

"Global Population Sequencing Market to Reach $64,047.6 Million by 2030."

Market Report Coverage - Global Population Sequencing Market

Market Segmentation

  • Product Type - Kits and Assays, Platforms, Software Tools
  • Application- Human Health, Molecular Forensics, Blockchain in Genomics
  • Methods- Whole Genome Sequencing, Whole Exome Sequencing, Single-Read Sequencing, and Other Sequencing Methods
  • Technology- Next-Generation Sequencing, Polymerase Chain Reaction and Other Technologies

Growth Drivers

  • Rising Adoption of Large-Scale Sequencing to Understand the Genomics of Susceptibility and Resistance from COVID-19
  • Increasing Adoption of Personalized Medicine for the Screening and Diagnostics of Genetic Disorders
  • Global Surge in Direct-to-Consumer (DTC) Genetic Testing

Market Challenges

  • Lack of Infrastructure to Maintain, Store and Share Sensitive Genomic Data
  • Absence of Sufficient Funding for Development of High-Throughput Genomic Software Tools
  • Poor Reducibility and Translatability of Data in Clinical Practice

Market Opportunities

  • Advancing Precision Medicine with Blockchain-Powered Artificial Intelligence
  • Technological Advancements in Sample Preparation for Population Sequencing
  • Increased Population Engagement and Data Management

Key Companies Profiled

Thermo Fisher Scientific, Illumina Inc., Pacific Biosciences of California, Inc., Qiagen N.V., Oxford Nanopore Technologies, Inc., and Agilent Technologies, Inc., Genuity Science, F. Hoffman La-Roche Ltd., Nebula Genomics, Inc., Helix Opco, LLC, Beijing Genomics Institute, and Agilent Technologies, Inc.

Key Questions Answered in this Report:

  • What are the major market drivers, challenges, and opportunities in the global population sequencing market?
  • What is the potential impact of sequencing and biotechnological advancement in the application of genomic medicine and translational research?
  • What is the current market expense along with future expected expenses in population sequencing initiatives?
  • How population sequencing helped genomic tests to become a prominent tool for diagnostics in various clinical applications?
  • What are the key development strategies which are implemented by the major players in order to sustain in the competitive market?
  • How is each segment of the market expected to grow during the forecast period from 2020 to 2030 based on:
    • product type
    • method
    • application
    • technology
    • country
  • Who are the leading players with significant offerings to the global population sequencing market? What is the expected market dominance for each of these leading players?
  • Which emerging companies are anticipated to be highly disruptive in the future, and what are their key strategies for sustainable growth in the population sequencing industry?

Market Overview

As per BIS Research analysis, the population sequencing market is projected to reach $64,047.6 million by 2030 from $21,730.4 million in 2020, at a CAGR of 11.41% during the forecast period, 2020-2030. Growth in this market is expected to be driven by the rising adoption of large-scale sequencing to understand the genomics of susceptibility and resistance from COVID-19, increasing adoption of personalized medicine for the screening and diagnosis of genetic disorders, and a global surge in direct-to-consumer genetic testing. However, there are significant challenges that are restraining the market growth, such as lack of infrastructure to maintain, store, and share sensitive genomic data, absence of sufficient funding for the development of high-throughput genomic software tools, and poor reducibility and transability of data in clinical practice.

The market is favored by the technological advancements in the sequencing, and computational analysis solutions for large volume of genetic data enabling deep understanding of the genetic variants for the development of diagnostics, drug discovery, and translational research.

Furthermore, several sequencing companies are focusing on the development of high-throughput sequence platforms and polymerase chain reaction platforms, with higher sensitivity and low turn-around time to benefit the patients, enabling patient-based outcomes and implementing genomic medicine.

Within the research report, the market is segmented on the basis of product type, application, methods, and technology. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the application of precision medicine on the global level has created a buzz among companies to invest in the development of rapid diagnostics providing information on genetic mutation and optimal candidates for adjuvant chemotherapy or hormonal therapy. Due to the diverse product portfolio and intense market penetration, Illumina, Inc. has been a pioneer in this field and has been a significant competitor in this market.

The population sequencing market provided immense growth opportunities for the companies providing technology and infrastructure for large-scale health initiatives, such as Color Genomics, Inc., Helix Opco, LLC, and big data companies such as Genuity Science

Table of Contents

Executive Summary

1 Product Definition

  • 1.1 Definition by Product
    • 1.1.1 Platforms
    • 1.1.2 Kits and Assays
    • 1.1.3 Software Tools
  • 1.2 Inclusion and Exclusion
    • 1.2.1 Inclusion and Exclusion for Country-Wise Market Estimation
  • 1.3 Scope of Work
  • 1.4 Key Questions Answered in the Report

2 Research Methodology

  • 2.1 Primary Data Sources
  • 2.2 Secondary Data Sources
  • 2.3 Market Estimation Model
  • 2.4 Criteria for Company Profiling

3 Introduction

  • 3.1 Market Overview
  • 3.2 Impact of COVID-19 on Population Sequencing
  • 3.3 Future Potential

4 Global Population Sequencing Market Dynamics

  • 4.1 Overview
  • 4.2 Impact Analysis
  • 4.3 Market Drivers
    • 4.3.1 Rising Adoption of Large-Scale Sequencing to Understand the Genomics of Susceptibility and Resistance from COVID-19
    • 4.3.2 Increasing Adoption of Personalized Medicine for the Screening and Diagnostics of Genetic Disorders
    • 4.3.3 Global Surge in Direct-to-Consumer (DTC) Genetic Testing
  • 4.4 Market Restraints
    • 4.4.1 Lack of Infrastructure to Maintain, Store and Share Sensitive Genomic Data
    • 4.4.2 Absence of Sufficient Funding for Development of High-Throughput Genomic Software Tools
    • 4.4.3 Poor Reducibility and Translatability of Data in Clinical Practice
  • 4.5 Market Opportunity
    • 4.5.1 Advancing Precision Medicine with Blockchain-Powered Artificial Intelligence
    • 4.5.2 Technological Advancements in Sample Preparation for Population Sequencing
    • 4.5.3 Increased Population Engagement and Data Management

5 Competitive Landscape

  • 5.1 Key Strategies and Developments
    • 5.1.1 Product Approval
    • 5.1.2 Product Launches and Upgradations
    • 5.1.3 Synergistic Activities
    • 5.1.4 Funding and Expansion
    • 5.1.5 Acquisitions
    • 5.1.6 Other

6 Industry Insights

  • 6.1 Overview
  • 6.2 Legal Requirements and Framework in the U.S.
  • 6.3 Legal Requirements and Framework in Europe
  • 6.4 Legal Requirements and Framework in Asia-Pacific
    • 6.4.1 Japan
  • 6.5 Market Share Analysis (by Company) 2019
    • 6.5.1 Growth Share Analysis (Opportunity Mapping)
    • 6.5.2 By Company

7 Global Population Sequencing Initiatives (by Country)

  • 7.1 U.S.
  • 7.2 Canada
    • 7.2.1 Population Sequencing Program
  • 7.3 The U.K.
    • 7.3.1 Industrial Partnership Directing the Course of Genomic Medicine
  • 7.4 Estonia
  • 7.5 Germany
  • 7.6 France
  • 7.7 Ireland
  • 7.8 Netherlands
  • 7.9 Denmark
  • 7.1 Japan
  • 7.11 China
  • 7.12 Australia
  • 7.13 Saudi Arabia
  • 7.14 Qatar
  • 7.15 Turkey
  • 7.16 Dubai

8 Global Population Sequencing Market (by Product), $Million, 2019-2030

  • 8.1 Introduction
  • 8.2 Kits and Assays
  • 8.3 Platforms
  • 8.4 Software Tools

9 Global Population Sequencing Market (by Methods), $Million, 2019-2030

  • 9.1 Introduction
  • 9.2 Whole Genome Sequencing
  • 9.3 Whole Exome Sequencing
  • 9.4 Single-Read Sequencing
  • 9.5 Other Sequencing Methods

10 Global Population Sequencing Market (by Technology), $Million, 2019-2030

  • 10.1 Introduction
  • 10.2 Polymerase Chain Reaction (PCR)
  • 10.3 Next Generation Sequencing (NGS)
  • 10.4 Other Technologies

11 Global Population Sequencing Market (by Application), $Million, 2019-2030

  • 11.1 Introduction
  • 11.2 Human health
    • 11.2.1 Clinical Applications
      • 11.2.1.1 Diagnostics
        • 11.2.1.1.1 Cancer Diagnostics
        • 11.2.1.1.2 Infectious Disease Diagnostics
        • 11.2.1.1.3 Rare Disease Diagnostics
        • 11.2.1.1.4 Other Diagnostics
      • 11.2.1.2 Drug Discovery and Development
    • 11.2.2 Translational Research Sequencing
  • 11.3 Molecular Forensics
  • 11.4 Blockchain in Genomics
    • 11.4.1 Data Sharing and Monetization
    • 11.4.2 Data Storage and Security
    • 11.4.3 Automated Health Insurance

12 Global Population Sequencing Market (by Country), $Million, 2019-2030

  • 12.1 U.S. Population Sequencing Market, $Million, 2019-2030
  • 12.2 Canada Population Sequencing Market, $Million, 2019-2030
  • 12.3 U.K. Population Sequencing Market, $Million, 2019-2030
  • 12.4 Germany Population Sequencing Market, $Million, 2019-2030
  • 12.5 Denmark Population Sequencing Market, $Million, 2019-2030
  • 12.6 Ireland Population Sequencing Market, $Million, 2019-2030
  • 12.7 Estonia Population Sequencing Market, $Million, 2019-2030
  • 12.8 Finland Population Sequencing Market, $Million, 2019-2030
  • 12.9 Netherlands Population Sequencing Market, $Million, 2019-2030
  • 12.1 China Population Sequencing Market, $Million, 2019-2030
  • 12.11 Japan Population Sequencing Market, $Million, 2019-2030
  • 12.12 Saudi Arabia Population Sequencing Market, $Million, 2019-2030
  • 12.13 Turkey Population Sequencing Market, $Million, 2019-2030
  • 12.14 Qatar Population Sequencing Market, $Million, 2019-2030

13 Company Profiles

  • 13.1 Agilent Technologies, Inc.
    • 13.1.1 Company Overview
    • 13.1.2 Role of Agilent Technologies, Inc. in Global Population Sequencing Market
    • 13.1.3 Financials
    • 13.1.4 Key Insights About Financial Health of the Company
    • 13.1.5 SWOT Analysis
  • 13.2 Beijing Genomics Institute (BGI)
    • 13.2.1 Company Overview
    • 13.2.2 Role of BGI in Global Population Sequencing Market
    • 13.2.3 SWOT Analysis
  • 13.3 Color Genomics, Inc.
    • 13.3.1 Company Overview
    • 13.3.2 Role of Color Genomics, Inc. in Global Population Sequencing Market
    • 13.3.3 SWOT Analysis
  • 13.4 F. Hoffmann-La Roche Ltd
    • 13.4.1 Company Overview
    • 13.4.2 Role of F. Hoffmann-La Roche Ltd in Global Population Sequencing Market
    • 13.4.3 Financials
    • 13.4.4 Key Insights About Financial Health of the Company
    • 13.4.5 SWOT Analysis
  • 13.5 Genuity Science
    • 13.5.1 Company Overview
    • 13.5.2 Role of Genuity Science in Global Population Sequencing Market
    • 13.5.3 SWOT Analysis
  • 13.6 Helix OpCo, LLC
    • 13.6.1 Company Overview
    • 13.6.2 Role of Helix Opco, LLC in Global Population Sequencing Market
    • 13.6.3 SWOT Analysis
  • 13.7 Illumina, Inc.
    • 13.7.1 Company Overview
    • 13.7.2 Role of Illumina, Inc. in Global Population Sequencing Market
    • 13.7.3 Financials
    • 13.7.4 Key Insights About Financial Health of the Company
    • 13.7.5 SWOT Analysis
  • 13.8 Nebula Genomics, Inc.
    • 13.8.1 Company Overview
    • 13.8.2 Role of Nebula Genomics, Inc. in Global Population Sequencing Market
    • 13.8.3 SWOT Analysis
  • 13.9 Oxford Nanopore Technologies, Inc.
    • 13.9.1 Company Overview
    • 13.9.2 Role of Oxford Nanopore Technologies, Inc. in Global Population Sequencing Market
    • 13.9.3 SWOT Analysis
  • 13.1 Pacific Biosciences of California, Inc.
    • 13.10.1 Company Overview
    • 13.10.2 Role of Pacific Biosciences of California, Inc. in Global Population Sequencing Market
    • 13.10.3 Financials
    • 13.10.4 Key Insights About Financial Health of the Company
    • 13.10.5 SWOT Analysis
  • 13.11 QIAGEN N.V.
    • 13.11.1 Company Overview
    • 13.11.2 Role of QIAGEN N.V. in Global Population Sequencing Market
    • 13.11.3 Financials
    • 13.11.4 Key Insights About Financial Health of the Company
    • 13.11.5 SWOT Analysis
  • 13.12 Thermo Fisher Scientific Inc.
    • 13.12.1 Company Overview
    • 13.12.2 Role of Thermo Fisher Scientific Inc. in Global Population Sequencing Market
    • 13.12.3 Financials
    • 13.12.4 Key Insights About Financial Health of the Company
    • 13.12.5 SWOT Analysis